Overview

A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib

Status:
Completed

Trial end date:
2010-04-23

Target enrollment:

Participant gender:

Summary

This is a single-arm, open-label, multicenter, international pilot study to evaluate changes that occur in 2-deoxy-2-[18F]fluoro-D-glucose (FDG)- and 3'-deoxy-3'-[18F]fluorothymidine(FLT)-PET (Positron Emission Tomography) imaging as a result of treatment with erlotinib in patients with recurrent or refractory non-small cell lung cancer (NSCLC). The study will enroll approximately 30 patients at approximately 4 sites in Australia and 2 sites in the United States.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Genentech, Inc.

Collaborator:

Roche Pharma AG

Treatments:

Alovudine
Dideoxynucleosides
Erlotinib Hydrochloride